| ID Source | ID |
|---|---|
| PubMed CID | 3516032 |
| CHEMBL ID | 1363249 |
| CHEBI ID | 93828 |
| SCHEMBL ID | 15781875 |
| Synonym |
|---|
| smr000151966 |
| MLS000564806 , |
| OPREA1_822381 |
| OPREA1_505728 |
| AKOS000808840 |
| AKOS016290565 |
| brd4354 |
| brd-4354 |
| BRD-A24054354-001-05-7 |
| sr-01000115983 |
| SR-01000115983-3 |
| 5-chloro-7-[(4-ethylpiperazin-1-yl)-pyridin-3-ylmethyl]quinolin-8-ol |
| BRD-A24054354-001-14-9 |
| dndi1417827 |
| CHEMBL1363249 |
| HMS2399C15 |
| SCHEMBL15781875 |
| 5-chloranyl-7-[(4-ethylpiperazin-1-yl)-pyridin-3-yl-methyl]quinolin-8-ol |
| cid_3516032 |
| 5-chloro-7-[(4-ethylpiperazino)-(3-pyridyl)methyl]quinolin-8-ol |
| bdbm49152 |
| 5-chloro-7-[(4-ethyl-1-piperazinyl)-(3-pyridinyl)methyl]-8-quinolinol |
| brd 4354 |
| 315698-07-8 |
| 5-chloro-7-[(4-ethyl-1-piperazinyl)-3-pyridinylmethyl]-8-quinolinol |
| STL487194 |
| 5-chloro-7-[(4-ethylpiperazin-1-yl)(pyridin-3-yl)methyl]quinolin-8-ol |
| SR-01000115983-1 |
| CHEBI:93828 |
| brd4354, >=98% (hplc) |
| Q27165560 |
| Z56842574 |
| CS-0062885 |
| HY-112719 |
| MS-26279 |
| 5-chloro-7-((4-ethylpiperazin-1-yl)(pyridin-3-yl)methyl)quinolin-8-ol |
| EN300-7562744 |
| Class | Description |
|---|---|
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 17.7828 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 22.3872 | 0.0184 | 6.8060 | 14.1254 | AID624172 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 39.8107 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 10.3225 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 19.9526 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 0.6310 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| Smad3 | Homo sapiens (human) | Potency | 11.2202 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 1.7783 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 12.5893 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 50.1187 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 11.2202 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| P53 | Homo sapiens (human) | Potency | 79.4328 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| IDH1 | Homo sapiens (human) | Potency | 5.8048 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.1220 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 14.1254 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 25.1189 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 3.9811 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 10.6213 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 2.5119 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 3.9151 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 35.4813 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| geminin | Homo sapiens (human) | Potency | 24.8446 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 63.0957 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 0.8913 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 25.1189 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nonstructural protein 1 | Influenza A virus (A/California/07/2009(H1N1)) | IC50 (µMol) | 17.7940 | 0.2000 | 24.4540 | 100.0000 | AID504329 |
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 18.0000 | 0.5800 | 26.5476 | 75.8000 | AID493003 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.3900 | 6.5441 | 29.1200 | AID1275 |
| estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 (µMol) | 2.3924 | 1.9109 | 8.3165 | 18.7976 | AID1060 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0004 | 0.6196 | 10.0000 | AID1801789 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0006 | 1.0526 | 10.0000 | AID1801789 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0001 | 0.5543 | 9.9000 | AID1801789 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0007 | 1.0260 | 9.9000 | AID1801789 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0001 | 0.7221 | 9.9700 | AID1801789 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0007 | 0.9947 | 9.9000 | AID1801789 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0005 | 0.9413 | 9.9000 | AID1801789 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 (µMol) | 25.1950 | 0.0007 | 0.9610 | 10.0000 | AID1801789 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 195.0000 | 0.1600 | 24.4900 | 236.5000 | AID2382 |
| heat shock protein 90 | Candida albicans | EC50 (µMol) | 55.5377 | 0.1200 | 6.4855 | 33.8530 | AID2387; AID2400; AID2423 |
| calcineurin A1, putative | Candida dubliniensis CD36 | EC50 (µMol) | 180.0000 | 4.6630 | 6.3810 | 8.0990 | AID2388 |
| recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 83.5500 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| aryl hydrocarbon receptor nuclear translocator | Homo sapiens (human) | AC50 | 4.0300 | 0.1900 | 23.3694 | 115.5100 | AID651703 |
| transforming acidic coiled-coil-containing protein 3 | Homo sapiens (human) | AC50 | 4.0300 | 0.1900 | 24.2333 | 115.5100 | AID651703 |
| replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 197.9950 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 13.9200 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 13.9200 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1911518 | Cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer. |
| AID1911516 | Cytotoxicity against human MES-SA cells assessed as cell growth inhibition incubated for 72 hrs by PrestoBlue reagent based cell viability assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer. |
| AID1911517 | Selectivity ratio of IC50 for cytotoxicity against human MES-SA cells assessed as cell growth inhibition to IC50 for cytotoxicity against multidrug resistance human MES-SA/Dx5 cells assessed as cell growth inhibition | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Structure-Activity Relationships of 8-Hydroxyquinoline-Derived Mannich Bases with Tertiary Amines Targeting Multidrug-Resistant Cancer. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1801789 | HDAC Enzymatic Assay from Article 10.1021/acschembio.6b00012: \\Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile.\\ | 2016 | ACS chemical biology, 07-15, Volume: 11, Issue:7 | Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||